bsm-52543R [Primary Antibody]
TCF7L2 (2C2) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TCF7L2

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 6934

Swiss Prot: Q9NQB0

Source: Human TCF7L2 aa 1-100

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.

Size: 100ul

Concentration: 1ug/ul

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Tao Zhang. et al. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. INT J BIOL SCI. 2022; 18(11): 45604577Read more>>
VALIDATION IMAGES

Flow cytometric analysis of Jurkat cells with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at a 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).


Jurkat cells lysate probed with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:1000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


IF(ICC) staining with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


IF(ICC) staining with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100 in SW480 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


IF(ICC) staining with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100 in D3 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


IF(ICC) staining with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100 in SW480 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human kidney tissue incubated with TCF7L2 (2C2) Monoclonal Antibody (bsm-52543R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


HepG2 cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20℃, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with TCF7L2 Monoclonal Antibody(bsm-52543R)at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).